Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Apyx Medical Corp. (APYX) Tops Q3 EPS by 5c, Revenues Beat
November 11, 2019 4:30 PM ESTApyx Medical Corp. (NASDAQ: APYX) reported Q3 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $6.78 million.
Our performance during the third quarter was impressive and represents a continuation of the better-than-expected growth and profitability performance we have generated throughout 2019, said Charlie Goodwin, President and Chief Executive Officer. I am extremely proud of the organizations ability to execute our strategic growth objectives and the progress we made during the third quarter is notable: we drove revenue growth of 106% year-over-year, led by 104%... More



